Merck & Co.
AWARDS
NEWS
Merck snapped up the company to gain ArQule’s lead investigational candidate, ARQ 531, a novel, oral Bruton’s tyrosine kinase inhibitor currently in a Phase II dose-expansion study for the treatment of B-cell malignancies.
According to PhRMA, there are 264 vaccines in development to prevent and treat diseases. These include infectious diseases (137), cancer (101), allergies (10), autoimmune disease (8) and Alzheimer’s disease (4).
Companies from across the globe provide updates on their businesses and pipelines.
As usual, it was a busy week for clinical trial updates. Here’s a look.
Pharma and biotech companies strengthen their leadership teams and boards with this week’s appointments.
The results of the Phase III VICTORIA trial set up the potential for the companies to seek regulatory approval for vericiguat.
JOBS
IN THE PRESS